NPM1 and myelodysplastic syndrome: Furthermore, Wright et al. [22], in a multicenter retrospective study of approximately 180 patients with NPM1-mut AML, reported that the presence of additional mutations in MDS-related genes did not have a negative impact on treatment outcomes.